Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.42 |
| ▸ | HTR2B | P41595 | 8/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1226267 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL292288 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1226165 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL1226270 | 1.00 | HTR2C (0.42) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL620204 | 0.90 | LMNA (0.45) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL620226 | 0.90 | LMNA (0.45) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL620225 | 0.90 | LMNA (0.45) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL626149 | 0.90 | LMNA (0.45) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL626148 | 0.90 | LMNA (0.45) | HTR2CHTR2AHTR2BLMNATSHR | |
| SCHEMBL6787733 | 0.87 | HTR2C (0.42) | HTR2CLMNATSHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | claimed |
| EP-2236511-A2 | LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | Alla Chem, LLC. (US) | 2010-10-06 | — | — | EP | claimed |
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ALLA CHEM, LLC (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2236511-A2 | LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF | Alla Chem, LLC. (US) | 2010-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039825-A1 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE | ADRB3, ADRA2C, ADRB2 | HTR2C 10/4885HTR2A 51/4885HTR2B 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.